Background: Currently, no specific immunohistochemical markers are available to differentiate primary mucinous epithelial ovarian cancer (MOC) from adenocarcinomas originating at other sites that have metastasised to the ovary, which may have an impact on patient management and prognosis.
Aim: To investigate the expression of two intestinal markers, galectin 4 and meprin α, in mucinous carcinomas of the ovary and gastrointestinal tract.
Methods: Using immunohistochemical analysis, the expression of galectin 4 and meprin α was investigated in 10 MOCs and in 38 mucinous adenocarcinomas of colon, pancreas, stomach and appendix, the most common sites of origin of ovarian metastases.
Results: Total cytoplasmic galectin 4 expression was relatively consistent between the different carcinomas. Membranous meprin α expression was significantly lower in MOCs compared with gastrointestinal carcinomas. Moreover, meprin α expression showed greater discrimination between the ovarian and gastrointestinal carcinomas than the cytokeratins CK7 and CK20, the current standard immunohistochemical markers used to determine the tissue origin of mucinous carcinomas involving the ovaries.
Conclusions: Meprin α is a useful additional marker in differentiating primary from secondary mucinous adenocarcinomas of the ovary.
- MOC, mucinous epithelial ovarian cancer
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Published Online First 5 July 2006
Funding: The Ovarian Cancer Project is a collaboration between the Royal Hospital for Women’s Gynaecological Cancer Centre and the Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia, and is supported by the Gynaecological Oncology (GO) Fund, Royal Hospital for Women’s Foundation, Randwick, New South Wales, Australia. VAH-S was supported by the Swiss National Foundation (FNSNF Number 81AM-068430), Division of Gynecology, University Hospital Zurich, Zurich, Switzerland. PMO’B and AVB are Fellows of the Cancer Institute New South Wales. RLS is supported by the National Health & Medical Research Council of Australia, and The Cancer Council New South Wales.
Competing interests: None.